Yes exactly, we are very unlikely to see an overall even slight improvement over baseline.
In which case the updated endpoint wording is on point.
Between the lines of my post was the idea; how to think but about however many 'super responders' that potentially are doing better than their baseline?
I think the answer has to be that before CTAD Ariana/Anavex are busy doing the stratification of the trial data on the various, first of all pre-specified, biomarkers.
I can't imagine Anavex would want to go to CTAD without also presenting any number of responders doing better at the end of the trial than their baseline and why - that would be BIG NEWS even if the number is < 81.
Bottom line is that we may not see Top Line Results PR before CTAD.
This because possible/likely extra exciting detail could not be mentioned in any detail without infringing on the TLD embargo. And more to the point, Anavex could not follow the legal advice of being very careful and precise about TLR PR while still doing a data deep dive without all the answers ready and solid.
Better in my opinion for Anavex to keep the TLD power dry assuming it isn't already damp.
Market Data 
Markets 
AI
